## 2019 MSTS Annual Meeting Preliminary Program

October 2-4, 2019 Marriott Portland Downtown Waterfront Hotel Portland, Oregon

James B. Hayden, MD, Program Chair Yee-Chen Doung, MD, Co-Chair R. Lor Randall, MD, FACS, MSTS President

## **Educational Goals and Objectives**

At the conclusion of this CME activity, the attendee should be able to:

Understand current trends in cancer research and treatment.

Review principles of Limb Salvage surgery.

Update understanding of the pathophysiology of metastatic bone disease.

Review overall management and operative approach to pelvic bone metastases.

Increase understanding of musculoskeletal treatment needs for adolescents and young adult cancer patients.

Update on basic science research in musculoskeletal oncology.

Identify current and future applications of Quality of Life assessments and patient reported outcomes.

Wednesday, October 2, 2019				
1:00 PM - 6:30 PM	Registration			
1:00 PM - 5:00 PM	Poster Set Up			
1:00 PM - 5:00 PM	Technical Exhibit Booth Set Up			
3:00 PM - 6:00 PM	MORI/MSTS Young Member Session			
6:30 PM - 8:30 PM	Welcome Reception - Mt Hood Room - Marriott Portland Do	wntown Waterfront Hotel		
Thursday, October 3, 2	2019			
6:30 AM - 5:30 PM	Registration			
7:00 AM - 8:30 AM	Breakfast			
7:00 AM - 5:30 PM	Poster/Technical Exhibits			
7:30 AM	Introduction and Welcome James Hayden, MD and R. Lor Randall, MD, FACS			
Session I: Registry	·			

Moderators: TBD			
		Surveillance After Extremity Tumor Surgery	
8:00 AM - 8:05 AM	Paper 1	(Safety) Patient Survey: A Patient Centered Approach To The Development Of An International Rct	Michelle Ghert, MD
6.00 AW - 6.05 AW	гарегі	Update On The American Academy Of	IMICHERE GREEK, MID
		Orthopaedic Surgeons Musculoskeletal	
8:05 AM - 8:10 AM	Paper 2	Tumor Registry	Benjamin J. Miller, MD, MS
		Affordable Care Act And Insurance Coverage In Orthopaedic Oncology: An Analysis Of The	
8:10 AM - 8:15 AM	Paper 3	Seer Database	Azeem Tariq Malik, MBBS
8:15 AM - 8:25 AM		Moderated Discussion	
Session II: Soft Tiss	sue Sarcoma		
Moderators: TBD			
8:25 AM -8:30 AM	Paper 4	Outcome After Surgical Treatment Of Dermatofibrosarcoma Protuberans (Dfsp): Does It Requires All This Follow Up? How Much Resection Margin Is Enough?	Ibrahim S Alshaygy, MD, MSC
8:30 AM - 8:35 AM	Paper 5	Interval Between Preoperative Radiation And Surgery Is Not Associated With Overall Survival For Soft Tissue Sarcomas: An Analysis Of The National Cancer Database	Christopher Collier, MD
8:35 AM - 8:40 AM	Paper 6	Metastatic Bone Disease At Diagnosis In Extremity Soft-Tissue Sarcomas: Risk Factors And Survival Analysis Using The Seer Registry	Manaf H.S. Younis, MD, MPH
8:40 AM - 8:50 AM	1 450. 0	Moderated Discussion	mana
8:50 AM - 8:55 AM	Paper 7	Early Outcomes Of Preoperative 5-Fraction Radiation Therapy For Soft Tissue Sarcoma With Immediate Resection	Joshua Michael Lawrenz, MD
8:55 AM - 9:00 AM	Paper 8	Improved Survivorship Following Surgical Resection Of The Primary Tumor In Patients With Metastatic Soft Tissue Sarcoma	Sophia A. Traven, MD

	1		1
		Neoadjuvant Combination Immunotherapy / Radiation For High-Risk Soft Tissue Sarcoma	
9:00 AM - 9:05 AM		(Nexis): Preliminary Results From An	
		Integrated Phase I/Ii, Single-Arm, Prospective	
	Paper 9	Clinical Trial	Vincent Y. Ng, MD
9:05 AM - 9:15 AM		Moderated Discussion	
		Extremity Malignant Peripheral Nerve Sheath	
		Tumor (Mpnst): A Retrospective Analysis Of	
9:15 AM - 9:20 AM	Paper 10	185 Cases From Reference Sarcoma Center	Bartek Szostakowski, MD
		Vascular Reconstruction In Sarcoma Surgery:	
		Complication, Functional And Vascular	
9:20 AM - 9:25 AM	Paper 11	Outcomes	Jean-Camille Mattei, MD
0.2071111 0.2071111	Тарог тт	Leiemungen Description Description	,
0.05.4440.00.444	<b>D</b> 40	Leiomyosarcomas: Recurrence Rates Based On Tumor Depth	Flinch oth Mollings MD
9:25 AM - 9:30 AM	Paper 12	Moderated Discussion	Elizabeth Wellings, MD
9:30 AM - 9:40 AM 9:40 AM - 10:10 AM		Break	
9:40 AM - 10:10 AM 9:40 AM - 10:00 AM		Product Theater- TBD	
9:40 AM - 10:10 AM		Poster Viewing	
		i oster viewing	
Session III: Bone Tur	nors		
Moderators: TBD	_		
		Dona Curried Describer Of The Drimery	
		Does Surgical Resection Of The Primary Tumor In Patients With Metastatic	
40.40 AM 40.45 AM	Donor 12		Canbia A Trayan MD
10:10 AM - 10:15 AM	Paper 13	Osteosarcoma Affect Survivorship	Sophia A. Traven, MD
		Age Versus Survival In Primary Bone	
		Cancers (Ewing's Sarcoma, Osteosarcoma,	
10:15 AM - 10:20 AM	Paper 14	And Chondrosarcoma)	William G Ward, MD, FACS
		Targeted Muscle Reinnervation Decreases	
		Phantom And Residual Limb Pain In	
10:20 AM - 10:25AM	Paper 15	Oncologic Amputees	John Alexander, MD
	'	Moderated Discussion	,
10:25 AM -10:35 AM			
Session IV: Surgical	Treatment		
Moderators: TBD			

10:35 AM - 10:40 AM	Paper 16	Revision Rates For Megaprostheses: A Review Of The Literature And Meta-Analysis	Jean-Camille Mattei, MD*
10:40 AM - 10:45 AM	Paper 17	Custom Stem-Sideplate Preserves At-Risk Hip Joint During Endoprosthetic Reconstruction Of The Femur	Alexander Bryant Christ, MD*
10:45 AM - 10:50 AM	Paper 18	Bushing Design And Crosslinked Polyethylene Can Favorably Improve Mechanical Survival Of Rotating Hinge Endoprostheses Around The Knee	Robert M Henshaw, MD*
10:50 AM -11:00 AM	i apei io	Moderated Discussion	Trobert Witherlandw, Wib
11:00 AM - 11:05 AM	Paper 19	Intercalary Endoprosthetic Reconstruction: An Analysis Of Complications	Joseph Benevenia, MD
11:05 AM - 11:10 AM	Paper 20	Comparison Of Reconstructive Techniques Following Oncologic Intraarticular Resection Of Proximal Humerus	Matthew Thomas Houdek, MD
11:10 AM -11:15 AM	Paper 21	Bone Preservation Following Revision Allograft Prosthetic Composite Reconstruction Of The Proximal Humerus	Taylor James Reif, BS, M*
11:15 AM -11:25 AM	•	Moderated Discussion	,
11:25 AM -11:30 AM	Paper 22	Comparison Of Free Vascularized Fibula Grafting To Allograft Strut Grafting To Supplement Spinal Pelvic Reconstruction For Sacral Malignancies	Matthew Thomas Houdek, MD
11:30 AM -11:35 AM	Paper 23	Outcomes Of Sacral Tumor Resection Based On The Mayo Clinic Classification System	Peter S. Rose, MD
11:35 AM -11:40 AM	Paper 24	Navigation-Assisted In Pelvic And Sacrum Resection Provides Benefit In Minimizing Bony Recurrence	David M. Joyce, MD
11:40 AM -11:50 AM		Moderated Discussion	
11:50 PM - 1:00 PM		Lunch	
11.001 101 - 1.001 101		Lulion	

		In	
11:50 AM - 12:10 PM		Product Theater- TBD	
12:15 PM - 12:35 PM 11:50 AM - 1:00 PM		Product Theater- TBD Poster Viewing	
		•	
Session V: Panel Disc	ussion: Add	plescents and Young Adults	
4 00 514 4 40 514		Adolescents and Young Adults (AYA) Panel Discussion	
1:00 PM - 1:40 PM		Discussion	
Session VI: Young Ad	dults		
Moderators: TBD			
1:40 PM -1:45 PM	Paper 25	Pediatric Sarcoma Patients Have Worse Physical Function But Better Peer Relationships And Depressive Symptoms Than The U.S. General Pediatric Population As Measured By Promis	Anna R Cooper, MD, MPH
1:45 PM - 1:50 PM	Paper 26	Bisphosphonate Therapy For Treating Osteonecrosis In Pediatric Leukemia Patients: A Systematic Review	Shanaz Daneshdoost
1:50 PM - 1:55 PM	Paper 27	Allograft Reconstruction Alone Has An Increased Rate Of Amputation And Worse Functional Outcome When Compared With Vascularized Fibular Reconstruction For Tibial Defects In Pediatric Patients	Amirhossein Misaghi, MD*
1:55 PM - 2:00 PM	Paper 28	Clinical Characteristics Of Masses In Pediatric Hand/Wrist	Carlos D. Pargas, MD
2:00 PM - 2:10 PM	·	Moderated Discussion	_
2:10 PM - 2:15 PM	Paper 29	Low Socioeconomic Status Predicts Metastatic Disease At Presentation In Young Patients With Ewing Sarcoma	Sophia A. Traven, MD
2:15 PM - 2:20 PM	Paper 30	The Sarcoma-Specific Quality Of Life Study (Sarc-Qol) (Phase 1): Identifying Key Domains Of Health-Related Quality Of Life In Adult Patients With Extremity Soft Tissue Sarcoma	Krista Anne Goulding, MD, FRCSC, MPH

The Sarcoma-Specific Quality Of Life Study (Phase 1): A Qualitative Study Of Psychological Functioning And Coping Styles In Adult Extremity Soft Tissue Sarcoma Patients				
Psychological Functioning And Coping Styles In Adult Extremity Soft Tissue Sarcoma Patients  2:26 PM - 2:35 PM				
In Adult Extremity Soft Tissue Sarcoma   Patients   Rrista Anne Goulding, MD, FRCSC, MPH				
2:20 PM - 2:25 PM Paper 31 Patients Krista Anne Goulding, MD, FRCSC, MPH 2:25 PM - 2:35 PM Break Product Theater - TBD 2:35 PM - 3:05 PM Product Theater - TBD 2:35 PM - 3:05 PM Poster Viewing MSTS Business Meeting - MSTS Members 3:05 PM - 3:50 PM Since A Product Theater - TBD 3:05 PM - 3:50 PM Since A Product Theater - TBD 3:06 PM - 3:50 PM Since A Product Theater - TBD 3:07 PM Since A Product Theater - TBD 3:08 PM - 3:50 PM Since A Product Theater - TBD 3:09 PM - 3:55 PM Paper 32 Osteosarcoma Alexander Leandros Lazarides, MD 3:50 PM - 3:55 PM Paper 32 Osteosarcoma Alexander Leandros Lazarides, MD 3:55 PM - 4:00 PM Paper 33 Inhibition Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunophenotyping Defines Distinct Malignancy-Induced Immunophenotyping Defines Distinct Malignancy-Induced Immunophenotyping Moderated Discussion Brock A Lindsey, MD 4:05 PM - 4:05 PM Paper 34 Moderated Discussion Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening Ruichen Ma 4:05 PM - 4:20 PM Paper 35 Ruichen Ma Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human Name Paper Malignan Paper Maligna				
2.25 PM - 2.23 PM   Moderated Discussion   2.35 PM - 3.05 PM   Break   2.35 PM - 3.05 PM   Product Theater - TBD   2.35 PM - 3.05 PM   Product Theater - TBD   2.35 PM - 3.05 PM   Product Theater - TBD   2.35 PM - 3.05 PM   Poster Viewing   3.05 PM - 3.50 PM   Only    Session VII: Research   Moderators: TBD    A Cross-Species Personalized Medicine   Pipeline Identifies The Crm1 Export Pathway   As A Potentially Novel Treatment For   Osteosarcoma   Comparison Of Cachectic And Non-Cachectic   Sarcoma Patients Reveals Differences In The   Notch Pathway But Similarities In Myogenesis   Inhibition   Systems-Wide Immunophenotyping Defines   Distinct Malignancy-Induced Immunological   Changes That Follow Disease Burden In An   Immunocompetent K7m2 Orthotopic Murine   Model Of Osteosarcoma   Moderated Discussion   Brock A Lindsey, MD    4:05 PM - 4:15 PM   Paper 35   Paper 35   Paper 35   Poper Levels And Aldh1a1 Expression   Varies Between Low And Highly Metastatic   Human Osteosarcoma Cell Lines And Human			Datiente	
2:35 PM - 3:05 PM 2:35 PM - 2:56 PM Product Theater - TBD 2:35 PM - 3:05 PM Research Moderators: TBD  A Cross-Species Personalized Medicine Pipeline Identifies The Crm1 Export Pathway As A Potentially Novel Treatment For Osteosarcoma Comparison Of Cachectic And Non-Cachectic Sarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis Inhibition  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  Brock A Lindsey, MD  A:05 PM - 4:05 PM Roderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening Ruichen Ma Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human		Paper 31		Krista Anne Goulding, MD, FRCSC, MPH
2:35 PM - 2:55 PM 2:35 PM - 3:05 PM Product Theater - TBD Poster Viewing MSTS Business Meeting - MSTS Members Only  Session VII: Research Moderators: TBD  A Cross-Species Personalized Medicine Pipeline Identifies The Crm1 Export Pathway As A Potentially Novel Treatment For Osteosarcoma Alexander Leandros Lazarides, MD  Comparison Of Cachectic And Non-Cachectic Sarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis Inhibition Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma Brock A Lindsey, MD  4:05 PM - 4:15 PM Moderated Discussion Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening Ruichen Ma Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human				
2:35 PM - 3:05 PM  3:05 PM - 3:50 PM  Session VII: Research  Moderators: TBD  A Cross-Species Personalized Medicine Pipeline Identifies The Crm1 Export Pathway As A Potentially Novel Treatment For Osteosarcoma  Comparison Of Cachectic And Non-Cachectic Sarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis Jonathan Mandell, BS  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  Brock A Lindsey, MD  4:05 PM - 4:15 PM  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human				
MSTS Business Meeting - MSTS Members   Only				
3:05 PM - 3:50 PM  Session VII: Research  Moderators: TBD  A Cross-Species Personalized Medicine Pipeline Identifies The Crm1 Export Pathway As A Potentially Novel Treatment For Osteosarcoma  Comparison Of Cachectic And Non-Cachectic Sarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis Inhibition  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  Brock A Lindsey, MD  4:05 PM - 4:15 PM  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human	2:35 PM - 3:05 PM			
Session VII: Research  Moderators: TBD  A Cross-Species Personalized Medicine Pipeline Identifies The Crm1 Export Pathway As A Potentially Novel Treatment For Osteosarcoma Alexander Leandros Lazarides, MD  Comparison Of Cachectic And Non-Cachectic Sarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis Inhibition  3:55 PM - 4:00 PM Paper 33 Inhibition  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma Brock A Lindsey, MD  4:05 PM - 4:15 PM  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human			_	
A Cross-Species Personalized Medicine Pipeline Identifies The Crm1 Export Pathway As A Potentially Novel Treatment For Osteosarcoma  Comparison Of Cachectic And Non-Cachectic Sarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis Inhibition  Jonathan Mandell, BS  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  4:00 PM - 4:05 PM  Paper 34  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastattic Human Osteosarcoma Cell Lines And Human	3:05 PM - 3:50 PM		Only	
A Cross-Species Personalized Medicine Pipeline Identifies The Crm1 Export Pathway As A Potentially Novel Treatment For Osteosarcoma  Comparison Of Cachectic And Non-Cachectic Sarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis Inhibition  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  4:05 PM - 4:15 PM  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human		1		
Pipeline Identifies The Crm1 Export Pathway As A Potentially Novel Treatment For Osteosarcoma  3:50 PM - 3:55 PM  Paper 32  Comparison Of Cachectic And Non-Cachectic Sarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis Inhibition  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  Brock A Lindsey, MD  4:05 PM - 4:15 PM  A:15 PM - 4:20 PM  Paper 35  Pipeline Identifies The Crm1 Export Pathway As A Potentially Novel Treatment For Osteosarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis Inhibition  Jonathan Mandell, BS  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  Brock A Lindsey, MD  A:15 PM - 4:20 PM  Paper 35  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human	Moderators: TBD			
Pipeline Identifies The Crm1 Export Pathway As A Potentially Novel Treatment For Osteosarcoma  3:50 PM - 3:55 PM  Paper 32  Comparison Of Cachectic And Non-Cachectic Sarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis Inhibition  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  Brock A Lindsey, MD  4:05 PM - 4:15 PM  A:15 PM - 4:20 PM  Paper 35  Pipeline Identifies The Crm1 Export Pathway As A Potentially Novel Treatment For Osteosarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis Inhibition  Jonathan Mandell, BS  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  Brock A Lindsey, MD  A:15 PM - 4:20 PM  Paper 35  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human			A Cross-Species Personalized Medicine	
As A Potentially Novel Treatment For Osteosarcoma  Alexander Leandros Lazarides, MD  Comparison Of Cachectic And Non-Cachectic Sarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis Inhibition  3:55 PM - 4:00 PM  Paper 33  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  Brock A Lindsey, MD  4:05 PM - 4:15 PM  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human				
3:50 PM - 3:55 PM Paper 32 Osteosarcoma Alexander Leandros Lazarides, MD  Comparison Of Cachectic And Non-Cachectic Sarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis Inhibition  3:55 PM - 4:00 PM Paper 33 Inhibition  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  Brock A Lindsey, MD  4:05 PM - 4:15 PM  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human				
Comparison Of Cachectic And Non-Cachectic Sarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis Inhibition  3:55 PM - 4:00 PM  Paper 33  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  4:00 PM - 4:05 PM  Paper 34  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human	3:50 PM - 3:55 PM	Paper 32		Alexander Leandros Lazarides MD
Sarcoma Patients Reveals Differences In The Notch Pathway But Similarities In Myogenesis  3:55 PM - 4:00 PM  Paper 33  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  Paper 34  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human	0.00 i iii 0.00 i iii	, apo. 62		
Notch Pathway But Similarities In Myogenesis Inhibition  Jonathan Mandell, BS  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  Brock A Lindsey, MD  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human				
3:55 PM - 4:00 PM Paper 33 Inhibition Jonathan Mandell, BS  Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  4:00 PM - 4:05 PM Paper 34 Model Of Osteosarcoma  Brock A Lindsey, MD  4:05 PM - 4:15 PM Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human				
Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  Brock A Lindsey, MD  4:05 PM - 4:15 PM  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human	2:55 DM 4:00 DM	Donor 22	, , , , , , , , , , , , , , , , , , , ,	
Distinct Malignancy-Induced Immunological Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  Brock A Lindsey, MD  4:05 PM - 4:15 PM  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human	3.55 PIVI - 4.00 PIVI	rapel 33		Johannan Mandell, 55
Changes That Follow Disease Burden In An Immunocompetent K7m2 Orthotopic Murine Model Of Osteosarcoma  4:00 PM - 4:05 PM  Paper 34  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human				
Immunocompetent K7m2 Orthotopic Murine 4:00 PM - 4:05 PM Paper 34  Model Of Osteosarcoma  Brock A Lindsey, MD  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human				
4:00 PM - 4:05 PM  A:05 PM - 4:15 PM  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human				
4:05 PM - 4:15 PM  Moderated Discussion  Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  4:15 PM -4:20 PM  Paper 35  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human				
Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human	4:00 PM - 4:05 PM	Paper 34	Model Of Osteosarcoma	Brock A Lindsey, MD
Developing A Novel Spheroid Model For Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human				
Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human	4:05 PM - 4:15 PM		Moderated Discussion	
Chondrosarcoma Research And Drug Screening  Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human			Developing A Novel Spheroid Model For	
4:15 PM -4:20 PM Paper 35 Screening Ruichen Ma  Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human				
Copper Levels And Aldh1a1 Expression Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human				
Varies Between Low And Highly Metastatic Human Osteosarcoma Cell Lines And Human	4:15 PM -4:20 PM	Paper 35	<u> </u>	Ruichen Ma
Human Osteosarcoma Cell Lines And Human				
4:20 PM - 4:25 PM Paper 36 Samples Jonathan Mandell				
	4:20 PM - 4:25 PM	Paper 36	Samples	Jonathan Mandell

		Cell Cycle Checkpoints P16 And P21 –	
		Strong Predictors Of Clinicopathologic	
4:25 PM - 4:30 PM	Paper 37	Outcome In High-Grade Osteosarcoma	Elham Nasri, MD
4:30 PM - 4:40 PM		Moderated Discussion	
4:40 DM 4:45 DM	Danar 20	Safety And Feasibility Of The Civo Phase 0 Platform For Simultaneous Evaluation Of Multiple Drugs And Drug Combinations In The Tumor Microenvironment (Tme) Of Cancer Patients	Kenneth Gundle, MD
4:40 PM - 4:45 PM	Paper 38		Refilletti Gulidie, MD
4:45 PM - 4:50 PM	Paper 39	Mitigation Of Post-Radiation Muscle Fibrosis Using Tgf-Beta	Carol D Morris, MD, MS
		Treatment Of Soft Tissue Sarcoma With A	
4:50 PM - 4:55 PM	Paper 40	Novel Cold Plasma Jet	Alan T. Blank, MD, MS
4:55 PM - 5:05 PM		Moderated Discussion	
Session VIII: Miscel	laneous		
Moderators: TBD			
5:05 PM - 5:10 PM	Paper 41	The Downstream Revenue Impact Of A Dedicated Orthopaedic Oncologist	Zeke Walton, MD
5:10 PM - 5:15 PM	Paper 42	Are We Training Too Many Orthopaedic Oncologists?	Frank Chiarappa, MD
5:15 PM - 5:20 PM	Paper 43	Statistical Fragility Of Surgical And Procedural Clinical Trials In Orthopedic Oncology As Quantified By The Fragility Index: A Systematic Review	Eugene Jang, MD, MS
5:20 PM - 5:30 PM		Moderated Discussion	
5:30 PM		Meeting Adjourns	
	Social Event	- Portland World Trade Center	
Friday, October 4, 2	019		
6:30 AM- 8:30 AM	Registration		
7:00 AM - 8:30 AM	Breakfast		
7:00 AM - 11:45 AM	I Dantara /Tank	nical Exhibits	

Session IX: Metastatic			
Moderators: TBD			
7:30 AM - 7:35 AM	Paper 44	Outcomes In Metastatic Bone Disease: A Comparison Of Academic And Community Programs Using The National Cancer Database	Frank Chiarappa, MD
7:35AM - 7:40 AM	Paper 45	Survival In Patients With Carcinomas Presenting With Bone Metastasis At Diagnosis: A Seer Population-Based Cohort Study	Manaf H.S. Younis, MD, MPH
7:40 AM - 7:45 AM 7:45 AM - 7:55 AM	Paper 46	Survival After Surgery For Skeletal Metastases Is Associated With Preoperative Patient-Reported Assessments Moderated Discussion	Meredith Bartelstein, MD
7:55 AM - 8:00 AM	Paper 47	Multicenter Retrospective Comparison Of Failure Rates, Outcomes And Complications Between Plate And Nail Fixation For Metastatic Lesions Of The Humerus	James Norris, MD
8:00 AM - 8:05 AM	Paper 48	Finite Element Fracture Predictions For Patients With Metastatic Lesions Of The Proximal Femur	Timothy A Damron, MD
8:05 AM - 8:10 AM 8:10 AM - 8:20 AM	Paper 49	Can We Do Better Than Mirels In Predicting Fracture Risk For Patients With Multiple Myeloma? Evaluation Of A Novel Scoring System Moderated Discussion	Gregory Toci, BS
8:20 AM - 8:25 AM	Paper 50	The Use Of Arthroplasty When Treating Proximal Femur Metastatic Lesions Is Associated With Increased Patient Survival When Compared To Intramedullary Nailing In The Va Healthcare System	Kenneth Gundle, MD
8:25 AM - 8:30 AM	Paper 51	Beyond Bisphosphonates And Denosumab To Protect Bone From Cancer-Induced Bone Loss: Mechanism-Based Therapeutic Targets	Francis Young Lee, MD, PhD

		Does Nailing Of Pathologic Fractures	
8:30 AM - 8:35 AM	Paper 52	Increase Systemic Tumor Burden?	Carol D Morris, MD, MS
8:35 AM - 8:45 AM		Moderator Discussion	
8:45 AM - 9:45 AM		Presidential Guest Lecturer - Topic Title TBD	Theresa Guise, MD
9:45 AM - 10:15 AM		Break	
9:45 AM - 10:05 AM		Product Theater - TBD	
9:45 AM - 10:15 AM		Poster Viewing	
10:15 AM - 10:20 AM	Paper 53	Comparative Efficacy Of Receptor Tyrosine Kinase Inhibitors (Rtkis) And Immunotherapy (Anti-Pd-1/Pd-L1) For Treatment Of Osseous Versus Soft Tissue Metastases In Metastatic Renal Cell Carcinoma (Mrcc)	Katherine Tai
10:20 AM - 10:25 AM	Paper 54	Mutation Status And Treatment With Tyrosine Kinase Inhibitors Improves Survival Estimates In Patients With Metastatic Non-Small Cell Lung Cancer	Jonathan Agner Forsberg, MD, PHD
10:25 AM - 10:30 AM	Paper 55	Reamed Versus Unreamed Intramedullary Nailing For The Treatment Of Impending And Pathological Humeral Shaft Fractures: A Retrospective Comparative Study	Manaf H.S. Younis, MD, MPH
10:30 AM - 10:35 AM	i i	Moderator Discussion	
10:35 AM - 10:40 AM	Paper 56	Comparison Of Porous Tantalum Acetabular Implants Versus Harrington Reconstruction For Metastatic Disease Of The Acetabulum	Joshua Johnson, MD
10:40 AM - 10:45 AM	Paper 57	A Novel Percutaneous Osseous Pathway Screw Fixation Technique For Management Of Periacetabular Metastatic Disease	Sahitya Denduluri, MD
10:45 AM - 10:50 AM 10:50 AM - 11:00 AM	Paper 58	Ambulatory Minimally Invasive Image-Guided Ablation-Osteoplasty-Reinforcement-Internal Fixation (Aorif) Reconstruction For Osteolytic Metastatic Cancers In Weight Bearing Bones Moderated Discussion	Francis Young Lee, MD, PhD

11:00 AM - 11:05 AM	Paper 59	Pexidartinib For Locally Advanced Tenosynovial Giant Cell Tumor (Tgct): Overall Long-Term Pooled Efficacy And Safety With Characterization Of Hepatic Adverse Reactions (Ars) From Enliven And Other Studies	John H Healey, MD, FACS		
11:05 PM - 11:10 AM	Paper 60	Pvns Of The Knee: A Consecutive Series Of 54 Patients Treated Either Arthroscopically Or With Open Synovectomy	Jennifer Thomson		
		Retrospective Review Of Venous Thromboembolism Prophylaxis In Surgical Resection Of Benign And Malignant Tumors			
	Paper 61	Of Bone And Soft Tissue Moderated Discussion	Peter Kyriakides		
11:15 AM - 11:25 AM		!			
Session X: Panel Disc	Session X: Panel Discussion: Teach the Teacher				
11:30 AM - 12:30 PM		Teach the Teacher -Panel Discussion			
12:30 PM		Meeting Adjourns			

Thank you for attending the 2019 MSTS Annual Meeting.